Comparative Pharmacology
Head-to-head clinical analysis: DILOR versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR versus THEOVENT.
DILOR vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator